New insider activity at Kymera Therapeutics ( (KYMR) ) has taken place on March 4, 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Kymera Therapeutics has seen a wave of insider selling among its top executives. Chief Operating Officer Jeremy Chadwick sold 5,958 shares of Kymera Therapeutics stock for a total of $515,567. Chief Medical Officer Jared Gollob disposed of 10,508 shares, generating proceeds of $916,621. Meanwhile, Chief Financial Officer Bruce N. Jacobs sold 12,471 shares, with the transaction valued at $1,091,175. These coordinated sales by Kymera’s senior leadership highlight significant recent insider activity at the company.
Recent Updates on KYMR stock
Kymera Therapeutics saw multiple analyst price target increases over the last day, largely driven by confidence in its degradation platform after an upbeat Q4 earnings call and detailed pipeline update. Firms cited strong early efficacy and safety for KT‑621, a long cash runway into 2029, and validating partnerships with Gilead and Sanofi as key supports for a more favorable long‑term risk‑reward profile.
Additional support for higher targets came from the launch of pivotal‑enabling Phase IIb trials in atopic dermatitis and asthma, together with the first‑in‑human Phase 1 start for KT‑579, which broadens Kymera’s autoimmune pipeline. While rising R&D spend, modest current revenue, and long timelines to commercialization were acknowledged as risks, analysts emphasized that steady clinical progress and multiple upcoming data catalysts justify revisiting valuation assumptions and lifting price expectations.
Spark’s Take on KYMR Stock
According to Spark, TipRanks’ AI Analyst, KYMR is a Neutral.
The score is driven by strong pipeline momentum and funding/runway from the latest earnings call, plus a clear uptrend in the stock’s technical setup. Offsetting these positives are weak current financial performance (large losses and substantial free-cash-flow burn) and limited valuation support given the negative P/E and no dividend.
To see Spark’s full report on KYMR stock, click here.
More about Kymera Therapeutics
YTD Price Performance: 10.98%
Average Trading Volume: 1,032,260
Technical Sentiment Signal: Buy
Current Market Cap: $7.05B